{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:14:29Z","timestamp":1789992869982,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer\u2019s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, potential enrollment barriers in the pre-dementia population are relatively under-reported. In a large European longitudinal biomarker study (the AMYPAD-PNHS), we investigated main enrollment barriers in individuals with no or mild symptoms recruited from research and clinical parent cohorts (PCs) of ongoing observational studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Logistic regression was used to predict study refusal based on sex, age, education, global cognition (MMSE), family history of dementia, and number of prior study visits. Study refusal rates and categorized enrollment barriers were compared between PCs using chi-squared tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>535\/1856 (28.8%) of the participants recruited from ongoing studies declined participation in the AMYPAD-PNHS. Only for participants recruited from clinical PCs (<jats:italic>n<\/jats:italic>\u2009=\u2009243), a higher MMSE-score (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.22, OR\u2009=\u20090.80, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05), more prior study visits (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.93, OR\u2009=\u20090.40, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), and positive family history of dementia (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20092.08, OR\u2009=\u20098.02, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01) resulted in lower odds on study refusal. General study burden was the main enrollment barrier (36.1%), followed by amyloid-PET related burden (PC<jats:sub>research<\/jats:sub>\u2009=\u200927.4%, PC<jats:sub>clinical<\/jats:sub>\u2009=\u20099.0%, <jats:italic>X<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u200910.56, <jats:italic>p<\/jats:italic>\u2009=\u2009.001), and loss of research interest (PC<jats:sub>clinical<\/jats:sub>\u2009=\u200946.3%, PC<jats:sub>research<\/jats:sub>\u2009=\u200916.5%, <jats:italic>X<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u200932.34, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The enrollment rate for the AMYPAD-PNHS was relatively high, suggesting an advantage of recruitment via ongoing studies. In this observational cohort, study burden reduction and tailored strategies may potentially improve participant enrollment into trial readiness cohorts such as for phase-3 early anti-amyloid intervention trials.<\/jats:p>\n                <jats:p>The AMYPAD-PNHS (EudraCT: 2018\u2013002277-22) was approved by the ethical review board of the VU Medical Center (VUmc) as the Sponsor site and in every affiliated site.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-023-01332-4","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:01:55Z","timestamp":1698904915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study"],"prefix":"10.1186","volume":"15","author":[{"given":"Ilse","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora","family":"Lopes Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"V\u00e1llez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Hanseeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Kivipelto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Grau-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Gismondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Domingo","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AMYPAD consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"4","key":"1332_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1332_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frolich L, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9(1):60.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1332_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"key":"1332_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41582-022-00645-6","volume":"18","author":"PS Aisen","year":"2022","unstructured":"Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022;18:389\u201399.","journal-title":"Nat Rev Neurol"},{"key":"1332_CR5","doi-asserted-by":"crossref","unstructured":"Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33\u2013cm33.","DOI":"10.1126\/scitranslmed.3002609"},{"issue":"1","key":"1332_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1): e12179.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"1332_CR7","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1332_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1332_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1332_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jalz.2016.10.001","volume":"12","author":"KN Fargo","year":"2016","unstructured":"Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z. The crisis in recruitment for clinical trials in Alzheimer\u2019s and dementia: an action plan for solutions. Alzheimers Dement. 2016;12(11):1113\u20135.","journal-title":"Alzheimers Dement"},{"key":"1332_CR11","doi-asserted-by":"crossref","unstructured":"Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, et al. Registries and cohorts to accelerate early phase Alzheimer\u2019s trials. A report from the E.U.\/U.S. clinical trials in Alzheimer\u2019s disease task force. J Prev Alzheimers Dis. 2016;3(2):68\u201374.","DOI":"10.14283\/jpad.2016.97"},{"issue":"1","key":"1332_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","volume":"12","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Albert M, Fox N, Goedert M, Kiyipelto M, Mestre-Ferrandiz J, Middleton LT. Why has therapy development for dementia failed in the last two decades? Alzheimers Dementia. 2016;12(1):60\u20134.","journal-title":"Alzheimers Dementia"},{"key":"1332_CR13","doi-asserted-by":"crossref","unstructured":"Isaksson E, Wester P, Laska AC, Nasman P, Lundstrom E. Identifying important barriers to recruitment of patients in randomised clinical studies using a questionnaire for study personnel. Trials. 2019;20(1).","DOI":"10.1186\/s13063-019-3737-1"},{"issue":"1","key":"1332_CR14","first-page":"24","volume":"477","author":"S Treweek","year":"2019","unstructured":"Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. Clin Orthop Relat R. 2019;477(1):24\u201330.","journal-title":"Clin Orthop Relat R"},{"issue":"2","key":"1332_CR15","first-page":"114","volume":"3","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, et al. Re-engineering Alzheimer clinical trials: Global Alzheimer\u2019s Platform Network. J Prev Alzheimers Dis. 2016;3(2):114\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"1332_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2015.11.007","volume":"39","author":"JD Grill","year":"2016","unstructured":"Grill JD, Zhou Y, Elashoff D, Karlawish J. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer\u2019s disease clinical trials. Neurobiol Aging. 2016;39:147\u201353.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"1332_CR17","doi-asserted-by":"publisher","first-page":"e0159664","DOI":"10.1371\/journal.pone.0159664","volume":"11","author":"M Calamia","year":"2016","unstructured":"Calamia M, Bernstein JPK, Keller JN. I\u2019d do anything for research, but I won\u2019t do that: interest in pharmacological interventions in older adults enrolled in a longitudinal aging study. PLoS One. 2016;11(7).","journal-title":"PLoS One"},{"issue":"4","key":"1332_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/WAD.0000000000000353","volume":"33","author":"JD Grill","year":"2019","unstructured":"Grill JD, Kwon J, Teylan MA, Pierce A, Vidoni ED, Burns JM, et al. Retention of Alzheimer disease research participants. Alzheimer Dis Assoc Disord. 2019;33(4):299\u2013306.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"1332_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-201081","volume":"80","author":"KK Indorewalla","year":"2021","unstructured":"Indorewalla KK, O\u2019Connor MK, Budson AE, Guess DiTerlizzi C, Jackson J. Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in Alzheimer\u2019s disease research. J Alzheimers Dis. 2021;80(3):927\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1332_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/JAD-2010-101536","volume":"23","author":"AL Jefferson","year":"2011","unstructured":"Jefferson AL, Lambe S, Chaisson C, Palmisano J, Horvath KJ, Karlawish J. Clinical research participation among aging adults enrolled in an Alzheimer\u2019s Disease Center research registry. J Alzheimers Dis. 2011;23(3):443\u201352.","journal-title":"J Alzheimers Dis"},{"key":"1332_CR21","doi-asserted-by":"crossref","unstructured":"Steinberg JR, Turner BE, Weeks BT, Magnani CJ, Wong BO, Rodriguez F, et al. Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020. Jama Netw Open. 2021;4(6):e2113749\u2013e.","DOI":"10.1001\/jamanetworkopen.2021.13749"},{"issue":"6","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cct.2006.06.007","volume":"27","author":"AL Fitzpatrick","year":"2006","unstructured":"Fitzpatrick AL, Fried LP, Williamson J, Crowley P, Posey D, Kwong L, et al. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo evaluation of memory study experience. Contemp Clin Trials. 2006;27(6):541\u201353.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"1332_CR23","first-page":"693","volume":"60","author":"SH Bardach","year":"2020","unstructured":"Bardach SH, Parsons K, Gibson A, Jicha GA. \u201cFrom victimhood to warriors\u201d: super-researchers\u2019 insights into Alzheimer\u2019s disease clinical trial participation motivations. Gerontologist. 2020;60(4):693\u2013703.","journal-title":"Gerontologist"},{"issue":"2","key":"1332_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40520-017-0771-2","volume":"30","author":"SH Bardach","year":"2018","unstructured":"Bardach SH, Holmes SD, Jicha GA. Motivators for Alzheimer\u2019s disease clinical trial participation. Aging Clin Exp Res. 2018;30(2):209\u201312.","journal-title":"Aging Clin Exp Res"},{"issue":"4","key":"1332_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","volume":"33","author":"JL Watson","year":"2014","unstructured":"Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA. Obstacles and opportunities in Alzheimer\u2019s clinical trial recruitment. Health Aff (Millwood). 2014;33(4):574\u20139.","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"1332_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/alzrt58","volume":"2","author":"JD Grill","year":"2010","unstructured":"Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer\u2019s disease clinical trials. Alzheimers Res Ther. 2010;2(6):34.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"1332_CR27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/gerona\/63.8.855","volume":"63","author":"JM Lai","year":"2008","unstructured":"Lai JM, Hawkins KA, Gross CP, Karlawish JH. Self-reported distress after cognitive testing in patients with Alzheimer\u2019s disease. J Gerontol A Biol Sci Med Sci. 2008;63(8):855\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1332_CR28","doi-asserted-by":"crossref","unstructured":"Grill JD, Karlawish J, Elashoff D, Vickrey BG. Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. Alzheimers Dement. 2013;9(3):356\u20139 e1.","DOI":"10.1016\/j.jalz.2012.03.001"},{"issue":"3","key":"1332_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jagp.2018.10.016","volume":"27","author":"CG Cox","year":"2019","unstructured":"Cox CG, Ryan BAMM, Gillen DL, Grill JD. A preliminary study of clinical trial enrollment decisions among people with mild cognitive impairment and their study partners. Am J Geriatr Psychiatry. 2019;27(3):322\u201332.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1332_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3233\/JAD-190146","volume":"69","author":"C Clement","year":"2019","unstructured":"Clement C, Selman LE, Kehoe PG, Howden B, Lane JA, Horwood J. Challenges to and facilitators of recruitment to an Alzheimer\u2019s disease clinical trial: a qualitative interview study. J Alzheimers Dis. 2019;69(4):1067\u201375.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1332_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13195-017-0311-5","volume":"9","author":"MM Nuno","year":"2017","unstructured":"Nuno MM, Gillen DL, Dosanjh KK, Brook J, Elashoff D, Ringman JM, Grill JD. Attitudes toward clinical trials across the Alzheimer\u2019s disease spectrum. Alzheimers Res Ther. 2017;9(1):81.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1332_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/gps.3958","volume":"29","author":"V Lawrence","year":"2014","unstructured":"Lawrence V, Pickett J, Ballard C, Murray J. Patient and carer views on participating in clinical trials for prodromal Alzheimer\u2019s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2014;29(1):22\u201331.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"1332_CR33","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16(5):750\u20138.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1332_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/alz.12292","volume":"17","author":"S Ingala","year":"2021","unstructured":"Ingala S, De Boer C, Masselink LA, Vergari I, Lorenzini L, Blennow K, et al. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement. 2021;17(7):1189\u2013204.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1332_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1332_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-021-00798-4","volume":"13","author":"JM Schaeverbeke","year":"2021","unstructured":"Schaeverbeke JM, Gabel S, Meersmans K, Luckett ES, De Meyer S, Adamczuk K, et al. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. Alzheimers Res Ther. 2021;13(1):75.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1332_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-018-0406-7","volume":"10","author":"E Konijnenberg","year":"2018","unstructured":"Konijnenberg E, Carter SF, ten Kate M, den Braber A, Tomassen J, Amadi C, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10(1):75.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1332_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10654-018-0459-8","volume":"34","author":"T Rydberg Sterner","year":"2019","unstructured":"Rydberg Sterner T, Ahlner F, Blennow K, Dahlin-Ivanoff S, Falk H, Havstam Johansson L, et al. The Gothenburg H70 Birth cohort study 2014\u201316: design, methods and study population. Eur J Epidemiol. 2019;34(2):191\u2013209.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"1332_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48(1):302\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1332_CR40","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/geronb\/gbaa152","volume":"76","author":"N Legdeur","year":"2021","unstructured":"Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, ten Kate M, et al. What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ study. J Gerontol. 2021;76(8):1499\u2013511.","journal-title":"J Gerontol"},{"issue":"S5","key":"1332_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.042628","volume":"16","author":"D Altomare","year":"2020","unstructured":"Altomare D, Collij L, Garibotto V, Poitrine L, Moro C, Alves IL, et al. Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. Alzheimers Dement. 2020;16(S5): e042628.","journal-title":"Alzheimers Dement"},{"key":"1332_CR42","unstructured":"Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols. J Prev Alzheimers Dis. 2017;4(2):100\u20138."},{"issue":"1","key":"1332_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-019-0576-y","volume":"12","author":"L Vermunt","year":"2020","unstructured":"Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, et al. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimers Res Ther. 2020;12(1):8.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"1332_CR44","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/jgs.16875","volume":"68","author":"ND Forsat","year":"2020","unstructured":"Forsat ND, Palmowski A, Palmowski Y, Boers M, Buttgereit F. Recruitment and retention of older people in clinical research: a systematic literature review. J Am Geriatr Soc. 2020;68(12):2955\u201363.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1332_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/geront\/gns079","volume":"55","author":"JC McHenry","year":"2015","unstructured":"McHenry JC, Insel KC, Einstein GO, Vidrine AN, Koerner KM, Morrow DG. Recruitment of older adults: success may be in the details. Gerontologist. 2015;55(5):845\u201353.","journal-title":"Gerontologist"},{"issue":"1","key":"1332_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12217","volume":"13","author":"F Ohman","year":"2021","unstructured":"Ohman F, Hassenstab J, Berron D, Scholl M, Papp KV. Current advances in digital cognitive assessment for preclinical Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2021;13(1): e12217.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1332_CR47","doi-asserted-by":"crossref","unstructured":"Lindberg JCH. \u2018J'accuse.!\u2019: the continuous failure to address radiophobia and placing radiation in perspective. J Radiol Prot. 2021;41(2).","DOI":"10.1088\/1361-6498\/abf9e2"},{"key":"1332_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnucene.2022.104280","volume":"149","author":"JCH Lindberg","year":"2022","unstructured":"Lindberg JCH, Archer D. Radiophobia: useful concept, or ostracising term? Prog Nucl Energy. 2022;149: 104280.","journal-title":"Prog Nucl Energy"},{"key":"1332_CR49","doi-asserted-by":"crossref","unstructured":"de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, et al. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers Res Ther. 2018;10(1):72.","DOI":"10.1186\/s13195-018-0398-3"},{"key":"1332_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/alz.12630","volume":"19","author":"AD Fruijtier","year":"2022","unstructured":"Fruijtier AD, van der Schaar J, van Maurik IS, Zwan MD, Scheltens P, Bouwman F, et al. Identifying best practices for disclosure of amyloid imaging results: a randomized controlled trial. Alzheimers Dement. 2022;19:285\u201395.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1332_CR51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2214\/AJR.10.5956","volume":"196","author":"LT Dauer","year":"2011","unstructured":"Dauer LT, Thornton RH, Hay JL, Balter R, Williamson MJ, St GJ. Fears, feelings, and facts: interactively communicating benefits and risks of medical radiation with patients. AJR Am J Roentgenol. 2011;196(4):756\u201361.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"1332_CR52","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JAD-170866","volume":"62","author":"M Boada","year":"2018","unstructured":"Boada M, Santos-Santos MA, Rodriguez-Gomez O, Alegret M, Canabate P, Lafuente A, et al. Patient engagement: the Fundacio ACE framework for improving recruitment and retention in Alzheimer\u2019s disease research. J Alzheimers Dis. 2018;62(3):1079\u201390.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 1","key":"1332_CR53","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.3233\/JAD-150189","volume":"48","author":"O Rodriguez-Gomez","year":"2015","unstructured":"Rodriguez-Gomez O, Abdelnour C, Jessen F, Valero S, Boada M. Influence of sampling and recruitment methods in studies of subjective cognitive decline. J Alzheimers Dis. 2015;48(Suppl 1):S99\u2013107.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1332_CR54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jalz.2019.02.003","volume":"15","author":"O Rodriguez-Gomez","year":"2019","unstructured":"Rodriguez-Gomez O, Rodrigo A, Iradier F, Santos-Santos MA, Hundemer H, Ciudin A, et al. The MOPEAD project: advancing patient engagement for the detection of \u201chidden\u201d undiagnosed cases of Alzheimer\u2019s disease in the community. Alzheimers Dement. 2019;15(6):828\u201339.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1332_CR55","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3233\/JAD-150455","volume":"50","author":"M Ibarria","year":"2016","unstructured":"Ibarria M, Alegret M, Valero S, Morera A, Guitart M, Canabate P, et al. Beneficial effects of an integrated psychostimulation program in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2016;50(2):559\u201366.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"1332_CR56","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jclinepi.2015.04.013","volume":"68","author":"KA Robinson","year":"2015","unstructured":"Robinson KA, Dinglas VD, Sukrithan V, Yalamanchilli R, Mendez-Tellez PA, Dennison-Himmelfarb C, Needham DM. Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. J Clin Epidemiol. 2015;68(12):1481\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1332_CR57","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1567205016666190321161901","volume":"16","author":"R Wong","year":"2019","unstructured":"Wong R, Amano T, Lin SY, Zhou Y, Morrow-Howell N. Strategies for the recruitment and retention of racial\/ethnic minorities in Alzheimer disease and dementia clinical research. Curr Alzheimer Res. 2019;16(5):458\u201371.","journal-title":"Curr Alzheimer Res"},{"key":"1332_CR58","doi-asserted-by":"crossref","unstructured":"Raman R, Quiroz YT, Langford O, Choi J, Ritchie M, Baumgartner M, et al. Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial. Jama Netw Open. 2021;4(7):e2114364\u2013e.","DOI":"10.1001\/jamanetworkopen.2021.14364"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01332-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01332-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01332-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T07:04:31Z","timestamp":1698908671000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01332-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01332-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The AMYPAD-PNHS (EudraCT: 2018\u2013002277-22) was approved by the ethical review board of the VU Medical Center (VUmc) as the Sponsor site and in every affiliated site. All of the participants provided written informed consent to participate in the study. The study was conducted following the Protocol and the Declaration of Helsinki and Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB has been a consultant for Araclon, Avid, Bayer, Elan, Grifols, Janssen\/Pfizer, Lilly, Neuroptix, Nutricia, Roche, Sanofi, Biogen, and Servier; and received fees for lectures and funds for research from Araclon, Esteve, Grifols, Janssen, Novartis, Nutricia, Piramal, Pfizer-Wyett, Roche, and Servier. Merc\u00e8 Boada received research funding from the Instituto de Salud Carlos III (ISCIII) Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa) grant PI17\/01474, and the European Union\/EFPIA Innovative Medicines Initiative Joint\u00a0 MOPEAD project (grant number 115985). MM received research funding from the Instituto de Salud Carlos III (ISCIII) Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa) grant PI19\/00335. DA received funding by the Fondation Recherche Alzheimer, and the Swiss National Science Foundation (project CRSK-3_196354 \/ 1). PS is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film\/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology. Presently he co-chairs the phase 3 study with NOVO-Nordisk. RV his institution has Clinical Trial Agreements (as PI) with Alector, Biogen, Janssen Pharmaceuticals, NovoNordisk, Prevail, Roche, UCB. His institution has consultancy agreements (RV as DSMB member) with AC Immune and Novartis. PS has an editorial role for the Alzheimer\u2019s Research & Therapy (AZRT) journal. RV was global PI of the Phase 1 and 2 18F-flutemetamol trials. RV institution had a material transfer agreement (RV as PI) with GEHC for free tracer delivery of the FPACK cohort baseline scans and with Avid Pharmaceuticals, an EliLilly subsidiary. BH received consulting fees from Biogen and Roche. The Belgian Foundation for Scientific Research supports his salary (FNRS CCL grant #40010417). He has received grants from the FNRS (including the WELBIO fund ##40010035), the Belgian Alzheimer Research Foundation (SAO-FRA), the Louvain and Saint-Luc Foundations, and the Queen Elizabeth Medical Foundation (QEMF-FMRE). MS has received fees for contributions to Advisory Boards from Roche, NovoNordisk and Servier and has received research support by Roche. MS has an editorial role for the AZRT journal. GBF reports grants from Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, IXICO, Merz Pharma, Nestl\u00e9, Novartis, Eisai, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, and Vifor Pharma; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, Roche, Diadem, Neurodiem, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics. FJ reported receiving personal fees from Biogen, personal fees from Eisai, personal fees from Roche, personal fees from AC Immune, personal fees from Janssen, personal fees from Danone\/Nutricia, personal fees from Lilly, personal fees from Grifols, and personal fees from Novo Nordisk outside the submitted work. FJ has an editorial role for the AZRT journal. AN received consulting fees from Hoffman La Roche. Patent: US patent alpha 7 nicotinic PET tracer. She is deputy chairman of Wennergren Foundations. MK has an editorial role for the AZRT journal. CWG has received fees for contributions to Advisory Boards from Biogen, Eisai, Eli Lilly, Roche, Roche Diagnostics, Actinogen, Alchemab, Merck, Kyowa Kirin, and Signant. His research has been supported by Janssen and Biogen. He was Chief Investigator of the IMI Funded EPAD project that had multiple EFPIA and SME partners. OG-R receives research support from Hoffmann La-Roche (paid to institution). JLM reported receiving grants from Innovative Medicines Initiative AMYPAD during the conduct of the study; being employed by Lundbeck and receiving consultancy fees from Genentech, Novartis, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, ProMIS Neurosciences, and Alector outside the submitted work. MS and LF are employees of Janssen Pharmaceuticals. AS and RG are employees of Life Molecular Imaging GmbH. JDG reported receiving grants from GE Healthcare, grants and personal fees from Roche Diagnostics, grants from Hoffmann La-Roche, personal fees from Biogen, and personal fees from Philips Nederland outside the submitted work. GF received research support from GE Healthcare (paid to institution). FB is in the steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics, FB h","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}